4 results about "Duck hepatitis A virus" patented technology

The invention discloses a recombinant duck enteritis virus for expressing 3-type duck hepatitis A virus immunogenic genes and a construction method and application thereof. The recombinant duck enteritis virus is characterized in that an eukaryotic expression cassette containing a type 3 duck hepatitis A virus immunogenic gene is inserted into a non-coding region between UL26 and USL27 genes of a duck enteritis virus genome. According to the invention, a duck hepatitis A virus (DHAV) immunogenic gene is inserted into a duck enteritis virus (DEV) genome at a fixed point by virtue of a CRISPR / Cas9 gene editing technology, so that the recombinant duck enteritis virus for expressing the duck hepatitis A virus type 3 immunogenic gene is constructed and obtained. Moreover, based on the recombinant duck enteritis virus for expressing the 3-type duck hepatitis A virus immunogenicity gene constructed by the invention, the exogenous DHAV immunogenicity gene can be stably expressed in the recombinant virus, and the recombinant virus has good in-vitro replication ability and hereditary stability and can be used for preparing animal vaccines.

The application discloses application of coenzyme Q10 and a composition containing coenzyme Q10 in preparation of a medicine for preventing and treating duck hepatitis A virus type 1, and relates to the technical field of veterinary antiviral medicines. The application finds through experiments that coenzyme Q10 and the composition containing coenzyme Q10 have a protective effect on duck hepatitis A virus type 1 infection. The composition contains coenzyme Q10 and egg yolk antibodies. The combination of coenzyme Q10 and egg yolk antibodies can relieve inflammatory reactions caused by duck hepatitis A virus type 1, reduce liver oxidative application, alleviate liver function damage caused by duck hepatitis A virus type 1, and reduce the viral load of duck hepatitis A virus type 1, so that the dual synergy of 'antiviral' and 'anti-inflammatory liver protection' is realized. The application first finds the application value of the combination of coenzyme Q10 and egg yolk antibodies in the prevention and treatment of DHAV-1 infection, and provides a new technical strategy for the prevention and treatment of duck viral hepatitis.

The invention belongs to the technical field of virus detection, and particularly relates to a PCR (Polymerase Chain Reaction) detection kit for four vertical transmission viruses of waterfowl and application of the PCR detection kit. The kit can rapidly, specifically and simultaneously amplify and diagnose duck hepatitis virus type I (DHV-1), duck Tembusu virus DTMUV, Muscovy duck reovirus MDRV and duck astrovirus DAstV, has high specificity and sensitivity, can accurately and rapidly identify DHV-1, DTMUV, MDRV and DAstV, can complete fluorescent quantitative PCR detection in about 50 minutes, and is simple to operate and practical. The detection period is shortened to 1.5 hours from 6-8 hours of a traditional method, the sensitivity is improved by 10-1000 times, the early diagnosis capability of epidemic diseases is remarkably improved, and the epidemic disease misjudgment rate of a farm is obviously reduced. Abuse of vaccines and drugs is reduced, and sustainable development of the poultry breeding industry is promoted.

This invention discloses the application of duck IL7 protein as an adjuvant in the preparation of duck hepatitis A virus type 3 inactivated vaccine, belonging to the field of biopharmaceuticals. The research of this invention shows that duck IL7 protein as an adjuvant can enhance the immunoprotective efficacy of the DHAV-3 inactivated vaccine and also enhance its heterologous protective ability. This provides a theoretical basis for the development of duck IL7 as a novel duck vaccine adjuvant.